HQL - Tekla Life Sciences Investors

NYSE - NYSE Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
375.69M
Enterprise Value 3
377.52M
Trailing P/E
40.24
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
177.60
Price/Book (mrq)
0.88
Enterprise Value/Revenue 3
178.47
Enterprise Value/EBITDA 6
N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 1.49
52-Week Change 3-6.48%
S&P500 52-Week Change 313.42%
52 Week High 318.02
52 Week Low 313.95
50-Day Moving Average 315.55
200-Day Moving Average 316.01

Share Statistics

Avg Vol (3 month) 384.18k
Avg Vol (10 day) 385.36k
Shares Outstanding 522.76M
Float N/A
% Held by Insiders 10.02%
% Held by Institutions 122.59%
Shares Short (Oct 31, 2019) 420.16k
Short Ratio (Oct 31, 2019) 40.22
Short % of Float (Oct 31, 2019) 4N/A
Short % of Shares Outstanding (Oct 31, 2019) 40.09%
Shares Short (prior month Sep 30, 2019) 422.34k

Dividends & Splits

Forward Annual Dividend Rate 41.48
Forward Annual Dividend Yield 48.92%
Trailing Annual Dividend Rate 31.55
Trailing Annual Dividend Yield 39.34%
5 Year Average Dividend Yield 48.90
Payout Ratio 4407.89%
Dividend Date 3Dec 31, 2018
Ex-Dividend Date 4Aug 27, 2019
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Sep 30, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 439.88%
Operating Margin (ttm)-160.19%

Management Effectiveness

Return on Assets (ttm)-0.49%
Return on Equity (ttm)2.16%

Income Statement

Revenue (ttm)2.12M
Revenue Per Share (ttm)0.09
Quarterly Revenue Growth (yoy)13.00%
Gross Profit (ttm)1.99M
EBITDA N/A
Net Income Avi to Common (ttm)9.3M
Diluted EPS (ttm)0.41
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)13.96
Book Value Per Share (mrq)18.68

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A